Skip to main content

Research Repository

Advanced Search

Do patient characteristics matter when calculating sample size for eczema clinical trials?

Howells, L.; Gran, S.; Chalmers, J. R.; Stuart, B.; Santer, M.; Bradshaw, L.; Gaunt, D. M.; Ridd, M. J.; Gerbens, L. A.A.; Spuls, P. I.; Huang, C.; Francis, N. A.; Thomas, K. S.

Authors

L. Howells

S. Gran

J. R. Chalmers

B. Stuart

M. Santer

L. Bradshaw

D. M. Gaunt

M. J. Ridd

L. A.A. Gerbens

P. I. Spuls

N. A. Francis

K. S. Thomas



Abstract

Background: The Patient-Oriented Eczema Measure (POEM) is the core outcome instrument recommended for measuring patient-reported atopic eczema symptoms in clinical trials. To ensure that the statistical significance of clinical trial results is meaningful, trials are often designed by specifying the target difference in the primary outcome as part of the sample size calculation. One method used to specify the target difference is a score that corresponds to a standardized effect size. Objectives: to assess how the standardized effect size of POEM scores vary across age, gender, ethnicity and disease severity. Methods: This study combined data from five UK-based randomized clinical trials of eczema treatments in order to assess differences in self-reported eczema symptoms (POEM) corresponding to a standardized effect size (0.5 SD of baseline POEM scores) across age, gender, ethnicity and disease severity. Results: POEM scores corresponding to 0.5 SD(baseline) were remarkably consistent across participants of varying ages, gender, ethnicity and disease severity from datasets of five UK trials in children (range 2.99–3.45). Conclusions: This study provides information that can support those designing clinical trials to determine their sample size and can aid individuals interpreting trial results. Further exploration of differences in populations beyond the United Kingdom is needed.

Citation

Howells, L., Gran, S., Chalmers, J. R., Stuart, B., Santer, M., Bradshaw, L., …Thomas, K. S. (2021). Do patient characteristics matter when calculating sample size for eczema clinical trials?. Skin Health and Disease, 1(3), Article e42. https://doi.org/10.1002/ski2.42

Journal Article Type Article
Acceptance Date Apr 22, 2021
Online Publication Date May 19, 2021
Publication Date Sep 1, 2021
Deposit Date Apr 4, 2022
Publicly Available Date Apr 7, 2022
Journal Skin Health and Disease
Electronic ISSN 2690-442X
Publisher John Wiley and Sons
Peer Reviewed Peer Reviewed
Volume 1
Issue 3
Article Number e42
DOI https://doi.org/10.1002/ski2.42
Public URL https://hull-repository.worktribe.com/output/3758974

Files

Published article (250 Kb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0

Copyright Statement
© 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.





You might also like



Downloadable Citations